Fennec Pharmaceuticals (NASDAQ:FENC) Announces Earnings Results

Fennec Pharmaceuticals (NASDAQ:FENC) posted its quarterly earnings data on Monday. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.62), Zacks reports. Fennec Pharmaceuticals had a negative return on equity of 53.38% and a negative net margin of 2.30%.

Fennec Pharmaceuticals Stock Up 1.0 %

FENC stock opened at $6.88 on Monday. The business has a 50 day moving average price of $6.39 and a two-hundred day moving average price of $5.61. The company has a market cap of $189.63 million, a price-to-earnings ratio of -68.79 and a beta of 0.36. Fennec Pharmaceuticals has a twelve month low of $3.96 and a twelve month high of $11.49.

Insider Buying and Selling at Fennec Pharmaceuticals

In other news, Director Rosty Raykov sold 10,000 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $6.79, for a total transaction of $67,900.00. Following the completion of the transaction, the director now directly owns 68,725 shares in the company, valued at approximately $466,642.75. The trade was a 12.70 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold a total of 31,186 shares of company stock worth $203,389 over the last ninety days. 10.98% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

FENC has been the topic of several research reports. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of Fennec Pharmaceuticals in a research note on Tuesday, December 17th. Stephens raised Fennec Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 18th. Finally, Wedbush reissued an “outperform” rating and issued a $13.00 target price on shares of Fennec Pharmaceuticals in a research report on Friday, December 20th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.